ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Catalent, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – CTLT
06 mars 2023 20h00 HE
|
The Rosen Law Firm PA
NEW YORK, March 06, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Catalent, Inc. (NYSE: CTLT) between August 30, 2021 and...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Catalent, and Tesla and Encourages Investors to Contact the Firm
01 mars 2023 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
Bone Therapeutics SA : Finalisation de l’acquisition de SCTS, sa filiale de production de thérapie cellulaire, par Catalent
16 nov. 2020 01h00 HE
|
Bone Therapeutics SA
INFORMATION RÉGLEMENTÉE Gosselies, Belgique, le 16 Novembre 2020, 7h00 CET – BONE THERAPEUTICS (Euronext Bruxelles et Paris : BOTHE), société de biotechnologie spécialisée dans le développement...
Bone Therapeutics announces completion of the acquisition of its cell therapy manufacturing subsidiary SCTS by Catalent
16 nov. 2020 01h00 HE
|
Bone Therapeutics SA
REGULATED INFORMATION Gosselies, Belgium, 16 November 2020, 7am CET – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics...
Bone Therapeutics signe des accords avec Catalent pour optimiser la production du produit de thérapie cellulaire allogénique ALLOB
29 oct. 2020 02h00 HE
|
Bone Therapeutics SA
INFORMATION RÉGLEMENTÉE Catalent acquiert la chaine de production de thérapie cellulaire de Bone Therapeutics pour 12 M€ Signature en parallèle d’un accord d’approvisionnement entre Bone...
Bone Therapeutics and Catalent sign agreements to streamline production of the allogeneic cell therapy product, ALLOB
29 oct. 2020 02h00 HE
|
Bone Therapeutics SA
REGULATED INFORMATION Catalent to acquire Bone Therapeutics’ cell therapy manufacturing facility for EUR 12 million Bone Therapeutics and Catalent shall enter into a supply agreement for...
Vectura Group appoints New Chief Executive Officer
29 oct. 2019 07h00 HE
|
Vectura Group plc
Vectura Group appoints New Chief Executive Officer Will Downie joins from Catalent Inc., one of the world’s largest Contract Development and Manufacturing Organisations Chippenham, UK – 29 October...
Medical Outsourcing Market Viewed As Crucial For Decreasing Global Medical Costs - IndustryARC Analysis
15 mars 2017 09h00 HE
|
IndustryARC
Hyderabad, India, March 15, 2017 (GLOBE NEWSWIRE) -- The report “Medical Outsourcing Market: By Services (Payer, Provider, Pharmaceutical, Pathology, Information Technology); By End Users...
Kannalife Sciences Announces Feasibility Study With Catalent Pharma Solutions for the Development of a Novel Cannabinoid Therapeutic Agent to Treat CTE and HE
29 févr. 2016 09h00 HE
|
Kannalife, Inc.
NEW YORK, Feb. 29, 2016 (GLOBE NEWSWIRE) -- Kannalife Sciences, Inc. (“Kannalife”), a Phyto-Medical Company, is pleased to announce the progress of its ongoing feasibility study being performed by...